GMH, thanks for the vote of confidence. I have the ability, all on my own, to look incredibly foolish at times when discussing what I think I heard in a conference call, an interview, or some other such communication.
And as I like to post quickly and then think later about what I wrote... well, I think you can guess the rest.
That said, I do agree that if the analysts remain conservative (and they have no reason not to as a benefit to their own clients), it should open the door to some trading opportunities. I also have a core position with no current reasons to sell any of it for the foreseeable future (18+ months or more). I also have a desire to build that position through various means, including trying to capture a little extra money selling near term puts (1-3 months out). I'll take any cash from the put money, assuming they expire worthless and roll that into some shares. or just buy the shares should the stock get put to me.
Another conference on March 26th could be insightful, albeit, more innuendo than actual numbers, but hopeful for some bonus info especially regarding current trials (though I do expect it to remain limited in that bonus material).
Good luck to you and all longs.
IMHO
And as I like to post quickly and then think later about what I wrote... well, I think you can guess the rest.
That said, I do agree that if the analysts remain conservative (and they have no reason not to as a benefit to their own clients), it should open the door to some trading opportunities. I also have a core position with no current reasons to sell any of it for the foreseeable future (18+ months or more). I also have a desire to build that position through various means, including trying to capture a little extra money selling near term puts (1-3 months out). I'll take any cash from the put money, assuming they expire worthless and roll that into some shares. or just buy the shares should the stock get put to me.
Another conference on March 26th could be insightful, albeit, more innuendo than actual numbers, but hopeful for some bonus info especially regarding current trials (though I do expect it to remain limited in that bonus material).
Good luck to you and all longs.
IMHO
Recent IOVA News
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/22/2026 09:15:00 PM
- Iovance Biotherapeutics to Present at Upcoming Conference • GlobeNewswire Inc. • 05/21/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 01:18:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:16:23 PM
- Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates • GlobeNewswire Inc. • 05/07/2026 11:05:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/01/2026 09:00:21 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 09:05:17 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 09:01:20 PM
- Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026 • GlobeNewswire Inc. • 04/27/2026 12:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/17/2026 09:15:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 04/17/2026 09:01:25 PM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (Canada) • 04/01/2026 12:49:00 AM
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step • PR Newswire (US) • 04/01/2026 12:49:00 AM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (US) • 03/24/2026 02:00:00 PM
- Advanced Cell-based Therapy Booming the Success for Healthcare Sector • PR Newswire (Canada) • 03/24/2026 02:00:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:02:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 10:00:12 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (Canada) • 03/05/2026 02:00:00 PM
- Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types • PR Newswire (US) • 03/05/2026 02:00:00 PM
